Gerald Walman, MD
Ophthalmology · Sun City, AZNPI 1730251836
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,763 of the $3,145 with a category attached, or 87.9%. It is spread thinly across 18 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $981 and has fallen 53.3% since, to $458 in 2025.
Across 47 payments — averaging $66.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$365
- Notal Vision, Inc.$330
- Bausch & Lomb, A Division Of Bausch Health US, LLC$321
- Alcon$306
- Sun Pharmaceutical Industries Inc.$287
- Glaukos Corporation$270
- plus $1K from 12 others
Across 351 payments — averaging $4907.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.6M
- Glaukos Corporation$79K
- Kala Pharmaceuticals, Inc.$27K
- Shire North American Group Inc$5K
What the payments were for
- Speaking & faculty fees$38112%
- Food & beverage$2,76388%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 8 | $365 |
| Notal Vision, Inc. | 1 | $330 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $321 |
| Alcon | 5 | $306 |
| Sun Pharmaceutical Industries Inc. | 4 | $287 |
| Glaukos Corporation | 2 | $270 |
| Rxsight Inc | 8 | $249 |
| AbbVie(2 entities) | 3 | $234 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $189 |
| Biotissue Holdings Inc. | 1 | $173 |
| Hoffmann-la Roche Limited | 1 | $136 |
| Dompe US, Inc. | 1 | $95 |
| Genentech USA, Inc. | 1 | $81 |
| Omeros Corporation | 1 | $31 |
| Shire North American Group Inc | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,145 in reported general payments places this provider in the 65th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 55 | $35,206 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $8,170 |
| Prednisolone Acetate | 131 | $7,102 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $3,482 |
| Travoprost | 19 | $2,566 |
| Latanoprost | 252 | $1,891 |
| Loteprednol Etabonate | 14 | $1,884 |
| Dorzolamide Hcl | 54 | $1,296 |
| Ketorolac Tromethamine | 68 | $1,201 |
| Ofloxacin | 127 | $1,200 |
| Timolol Maleate | 69 | $739 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 46 | $656 |
| ErythromycinErythromycin Base | 41 | $449 |
| Acetazolamide | 14 | $320 |
| Brimonidine Tartrate | 31 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $234 | $38,68867 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $321 | $1,88414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Sun City
- Michael HorsleySun City$9K
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Shamil PatelGlendale$116K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.